Comparable to the higher VAF of JAK2 in patients with BCR::ABL1-negative MPN, the higher BCR::ABL1 transcript level might be a risk factor for secondary BCR::ABL1-negative MPN in patients with CML. This evidence concerns the gene ABL1 and myeloproliferative neoplasm.